摘要
目的:研究布地奈德联合氨溴索治疗新生儿吸入性肺炎的临床疗效。方法:将88例患者随机分成两组,即对照组和实验组,每组44例,对照组采用新生儿吸入性肺炎的常规治疗方法,实验组在对照组基础上应用布地奈德联合氨溴索治疗,采用雾化吸入的方法,比较两组患儿治疗后的总有效率、临床症状、体征消失时间、住院时间、不良反应发生情况。结果:实验组患儿总有效率高于对照组,差异有统计学意义(P<0.05);实验组患儿的呼吸困难消失时间、紫绀消失时间、肺部啰音消失时间及住院时间均少于对照组,差异有统计学意义(P<0.05);两组在治疗过程中未发现药物不良反应。结论:布地奈德联合氨溴索治疗新生儿吸入性肺炎取得了较好的临床效果,有效的改善了患儿的临床症状和体征,不良反应少,用药安全可靠,利于患儿早日康复。
Objective: To study the clinical efficacy of budesonide jointed ambroxol in the treatment of neonatal aspiration pneumonia. Method: 88 patients were randomly divided into two groups, namely the control and experimental groups, each group of 44 patients. The control group was taken with conventional treatment of neonatal aspiration pneumonia, and the experimental group was taken with the budesonide ambroxol treatment and nebulized treatment on the basis of the control group. The total efficiency, the clinical symptoms and signs disappeared time, hospital stay, the incidence of adverse reactions for the two groups were compared. Result: The total efficiency in the experiment group was higher than that in the control group, the difference was statistically significant ( P〈0.05 ) . The breathing difficulties disappear, cyanosis disappeared time, lung Ministry rales disappear time and hospital stay in the experimental group were less than the control group, the difference was statistically significant ( P〈0.05 ) . There were no adverse drug reactions during treatment for the two groups of children. Conclusion: Budesonide jointed ambroxol in the treatment of neonatal aspiration pneumonia has achieved better clinical results, and improved the clinical signs and symptoms of adverse reactions, the medication is safe and reliable, which will help the speedy recovery of the children.
出处
《中国医学创新》
CAS
2013年第8期5-6,共2页
Medical Innovation of China
关键词
布地奈德
氨溴索
新生儿吸入性肺炎
临床疗效
Budesonide budesonide
Ambroxol
Neonatal aspiration pneumonia
Clinical efficacy